Search

Your search keyword '"Naparstek, Ella"' showing total 22 results
Start Over Author "Naparstek, Ella"
22 results on '"Naparstek, Ella"'

4. Treatment of Multiple Myeloma Using Chimeric Antigen Receptor T Cells with Dual Specificity

Author

Globerson Levin, Anat, primary, Rawet Slobodkin, Moran, additional, Waks, Tova, additional, Horn, Galit, additional, Ninio-Many, Lihi, additional, Deshet Unger, Naamit, additional, Ohayon, Yaara, additional, Suliman, Shimrit, additional, Cohen, Yael, additional, Tartakovsky, Boris, additional, Naparstek, Ella, additional, Avivi, Irit, additional, and Eshhar, Zelig, additional

Published
2020
Full Text
View/download PDF

6. Tellurium compound provides pro-apoptotic signaling in drug resistant multiple myeloma.

Author

Zigman-Hoffman, Eti, Sredni, Benjamin, Meilik, Benjamin, Naparstek, Ella, and Tartakovsky, Boris

Subjects
TELLURIUM compounds, MULTIPLE myeloma, MASS analysis (Spectrometry), DRUG resistance, STROMAL cells, FIBRONECTINS, MELPHALAN
Abstract

Multiple Myeloma, effectively treated by chemotherapeutic drugs, relapses due to drug resistance. We tested here the capacity of mesenchymal stromal cells, from the bone marrow of patients or from adipose tissue of healthy individuals, to induce drug resistance in Myeloma cell lines. We show that drug resistance can be achieved by factors secreted by the various MSC's. Mass spectrometry analysis of MSC's conditioned media revealed that fibronectin, was particularly instrumental in providing anti-apoptotic signals to MM cells. Moreover, we demonstrate that SAS ([octa-O-bis-(R,R)tartarate ditellurane]), an immunomodulator Tellurium compound, is not only able of blocking the physical interaction between MM cells and fibronectin but is also capable of re-sensitizing the cells to the chemotherapeutic drugs. Finally, we show that this re-sensitization is coupled with the blocking of pAKT induction, in MM cells, by the MSC's. These results indicate that SAS may be useful in the treatment of drug resistant MM. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

9. Toxicity and efficacy of autologous hematopoietic cell transplantation in elderly patients with aggressive lymphoma: a historical prospective study.

Author

Davidov, Marina, Perry, Chava, Herishanu, Yair, Sarid, Nadav, Rom, Esti, Amit, Odelia, Eshel, Rinat, Naparstek, Ella, Avivi, Irit, and Ram, Ron

Subjects
HEMATOPOIETIC stem cell transplantation, LYMPHOMAS, OLDER patients, MUCOSITIS, LUNG diseases, LYMPHOMA treatment, AGE distribution, AUTOGRAFTS, CANCER relapse, CANCER invasiveness, HOSPITAL care, LONGITUDINAL method, TREATMENT effectiveness
Abstract

High-dose therapy followed by autologous hematopoietic cell transplantation (HCT) prolongs overall survival in patients under 65 years old with relapsed aggressive lymphoma. We aimed to explore the toxicity and efficacy of HCT in patients over 65 years with aggressive lymphoma compared with younger patients. We compared the transplantation outcomes between patients ≥ 65 years (n = 58) and 55-64 years (n = 44) with chemosensitive aggressive lymphoma (DLBCL, MCL and TCL) that underwent HCT between 1999 and 2016 in the Tel-Aviv Medical Center. The median age was 68 (range, 65-74) and 61 (range, 55-64) years, respectively. There were no differences in the incidences of grade 3-4 mucositis, documented infections and pulmonary complications between the two groups. There was no difference in the incidences of secondary malignancies, relapse (p = .26), non-relapse mortality, (p = .77) and overall survival (p = .53). Multivariate analysis revealed that smoking was a risk factor for non-relapse mortality, while partial remission and > 2 lines of treatment prior HCT were associated with higher risk for relapse. Psycho-socioeconomic score was associated with prolonged hospitalization after HCT and recurrent hospitalizations. We conclude that patients ≥ 65 years old with aggressive lymphoma, compared to younger counterparts, have similar transplantation outcome. Improving habits and psychosocial factors may further improve outcomes in these patients. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

16. Nonmyeloablative Stem Cell Transplantation and Cell Therapy as an Alternative to Conventional Bone Marrow Transplantation With Lethal Cytoreduction for the Treatment of Malignant and Nonmalignant Hematologic Diseases

Author

Slavin, Shimon, primary, Nagler, Arnon, additional, Naparstek, Ella, additional, Kapelushnik, Yossi, additional, Aker, Memet, additional, Cividalli, Gabriel, additional, Varadi, Gabor, additional, Kirschbaum, Mark, additional, Ackerstein, Aliza, additional, Samuel, Simcha, additional, Amar, Avraham, additional, Brautbar, Chaim, additional, Ben-Tal, Ofira, additional, Eldor, Amiram, additional, and Or, Reuven, additional

Published
1998
Full Text
View/download PDF

21. SELECTIVE CD4+T-CELL DEPLETION DOES NOT PREVENT GRAFT-VERSUS-HOST DISEASE1

Author

Nagler, Arnon, Condiotti, Reba, Nabet, Corinne, Naparstek, Ella, Or, Reuven, Samuel, Simcha, and Slavin, Shimon

Abstract

Donor-derived CD4+T cells may play a role in the development of graft-versus-host disease (GVHD) and graft-versus-leukemia reaction after allogeneic bone marrow transplantation (BMT). Therefore, we evaluated the effect of CD4+T-cell depletion on GVHD and graft-versus-leukemia reaction after HLA-matched BMT. CD4 depletion was performed using anti-CD4 monoclonal antibodies and immunomagnetic beads, initially in small-scale experiments on bone marrow and granulocyte colony-stimulating factor-mobilized peripheral blood apheresis products. The result was elimination of the CD4+T cells from both sources (0% and 2±1.4% CD4+cells, respectively). Subsequently, we used this technique for large-scale negative selection of CD4+T cells from bone marrow grafts of four consenting leukemic patients in relapse (ALL-3, ANLL-1) (M-3, F-1). The large-scale CD4+T-cell depletion resulted in >98% (n=4) elimination of CD4+cells. The resulting population included 17.7±4.6% CD3+T cells, 8.9±2.5% CD8+T cells, 0.1±0.1% CD16+natural killer cells, and 2.3±3.2% CD34+hematopoietic progenitor cells. Patients were transplanted with 2.84±1.31×108viable cells/kg. They received cyclosporine starting on day -1 as GVHD prophylaxis. Engraftment was fast with a white blood cell count of >1×109/L on day 13.2±0.5, an absolute neutrophil count of >0.5×109/L on day 13.8±0.5, and a platelet count of >25×109/L on day 26.5±6.8. Immunological reconstitution was normal, and peripheral blood phenotyping 3 weeks after BMT disclosed 49.0±5.0% CD3, 14.3±12.4% CD4, and 59.5±7.8% CD8 T cells in addition to 17.0±3.0% CD16+and 9.0±3.0% CD56 natural killer cells. Three out of four patients developed very early grade IV GVHD beginning on day 12 (10-13) and died 2-4 months after BMT. One patient is alive and well with a follow-up of 36 months. We conclude that selective CD4 T-cell depletion does not prevent GVHD.

Published
1998

Catalog

Books, media, physical & digital resources
See catalog results